Hemab Therapeutics/X
Aug 13, 2025, 09:21
VELORA Discover Study Now Enrolling: Advancing Care for Type 1 Von Willebrand Disease
Hemab Therapeutics shared an inviting post on X:
”Now enrolling people living with Type 1 Von Willebrand disease (VWD) into the VELORA Discover study.
This observational study aims to deepen understanding of Type 1 VWD and help lay the groundwork for future advances in care.
If you are living with Type 1 VWD or treating people who are, learn more about how to participate.”
You can direct your inquiries to [email protected].
Stay informed on all opportunities in the field of bleeding disorders with Hemostasis Today.
-
Jul 2, 2026, 17:17Nico Gagelmann: Launching Myths and Facts on Hematology and Cell Therapy
-
Jul 2, 2026, 17:05Haroun Gajraj: Understanding the Technology Behind Spider Vein Treatment
-
Jul 2, 2026, 16:44Ney Carter Borges: Is It Time to Personalize Antiplatelet Therapy?
-
Jul 2, 2026, 16:22Introducing a New Resource for the ITP Community – ITP Support Association
-
Jul 2, 2026, 16:22Shinto Francis Thekkudan: Delegates Visiting our BMT and Hematology Department from Kazhakstan
-
Jul 2, 2026, 16:13William Aird: When Deciding whether an Adult Patient is Anemic, Which Do You Usually Use?
-
Jul 2, 2026, 16:08Supporting Bleeding Disorders Community and Celebrating ASPEH Milestone – WFH
-
Jul 2, 2026, 15:59Raul Santos: Why Does LDL-C Remain Elevated in Many Patients?
-
Jul 2, 2026, 15:16Tim Patel: How Regular Movement Helps Keep Blood Flowing Throughout the Day